Groningen, the Netherlands, 17 May 2011
MUCOSIS APPOINTS THOMAS JOHNSTON AS CHIEF BUSINESS OFFICER
--> Download the pdf
Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
“Tom has more than 15 years of business development experience and an in-depth understanding of the vaccine and biotechnology space. Therefore we are very pleased to welcome him to our team.” said Govert Schouten, Chief Executive Officer of Mucosis. “Through this appointment, we extend our business development reach for the success of our Mimopath®-based vaccine candidates."
Tom Johnston added: “I am excited to join the Mucosis management team. The company has made great progress to date and is now ready to move to broadening market awareness of its technology platform and vaccine pipeline.”
For further information please contact:
| Govert Schouten
CEO Mucosis B.V.
+31 (6) 55320948
Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath™ , on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM®, a vaccine to prevent influenza; PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM®, a vaccine to prevent RSV viral infection. Mimopath™ -based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.
About Mimopath® technology
The Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.